Effect of rivaroxaban on early osseointegration of implants

TANG Yue; ZHANG Xuan; ZHANG Xue-jian; YIN Chuan-rong; LIN Zhou-xing; DENG Yue

doi:10.19538/j.kq.2023.06.010

Abstract：Objective To study the effect of new oral anticoagulant rivaroxaban(RIV)on early implant osseointegra-tion.Methods The study was conducted in the central laboratory of Qingdao Stomatological Hospital from September 2019 to February 2020.12 white rabbits were randomly divided into a blank control group,an aspirin(ASP)group,and an RIV group,with 4 rabbits in each group.Three groups of white rabbits were perfused with physiological saline,ASP dissolved in physiological saline,and RIV dissolved in physiological saline,and test the differences in coagulation func-tion among the three groups of white rabbits.Totally 48 implants were placed by surgery,with 4 implants per white rab-bit.At the 2nd and 4th weeks after implantation,8 implants from 2 white rabbits in each group were selected for subse-quent research.Observe the morphology of the implant and surrounding bone tissue through Micro-CT,3D model recon-struction images,and implant-bone tissue specimen images.Compare the differences in bone-implant contact(BIC)among the three groups based on 3D model reconstruction and implant-bone tissue specimen images.Results After successful modeling,there was no statistically significant difference in coagulation function among the three groups of white rabbits(F=0.034,P=0.967).Micro-CT,3D model reconstruction images,and observation of implant bone tissue specimen images showed an increase in new bone formation around the implant at week 4 compared to week 2.At the 2nd and 4th week after surgery,the BIC of the blank control group and RIV group was higher than that of the ASP group,with statistical dif-ference(all P＜0.05);however,there was no statisti-cally significant difference in BIC between the blank control group and the RIV group(all P＞0.05).Moreover,the BIC of all three groups at week 4 was higher than that at week 2,and the differences were statistically significant(all P＜0.05).Conclusion Compared with the traditional anticoagulant drug-ASP,the new oral anticoagulant drug-RIV has no obvious inhibitory effect on the early implant osseointegration.